Analyzing Selectis Health (OTCMKTS:GBCS) and BioNexus Gene Lab (NASDAQ:BGLC)

BioNexus Gene Lab (NASDAQ:BGLC) and Selectis Health (OTCMKTS:GBCS) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, risk, analyst recommendations, earnings and institutional ownership.

Profitability

This table compares BioNexus Gene Lab and Selectis Health’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BioNexus Gene Lab	-54.70%	-37.43%	-32.88%
Selectis Health	-2.45%	N/A	-3.03%

Earnings and Valuation

This table compares BioNexus Gene Lab and Selectis Health”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNexus Gene Lab	$7.43 million	0.59	-$2.98 million	($1.48)	-1.22
Selectis Health	$41.44 million	0.39	-$1.02 million	($0.34)	-15.32

Selectis Health has higher revenue and earnings than BioNexus Gene Lab. Selectis Health is trading at a lower price-to-earnings ratio than BioNexus Gene Lab, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

BioNexus Gene Lab has a beta of 4.08, meaning that its share price is 308% more volatile than the S&P 500. Comparatively, Selectis Health has a beta of -1.07, meaning that its share price is 207% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations and price targets for BioNexus Gene Lab and Selectis Health, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNexus Gene Lab	1	0	0	0	1.00
Selectis Health	0	0	0	0	0.00

Institutional & Insider Ownership

18.9% of BioNexus Gene Lab shares are owned by institutional investors. 0.1% of BioNexus Gene Lab shares are owned by insiders. Comparatively, 15.2% of Selectis Health shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Selectis Health beats BioNexus Gene Lab on 7 of the 12 factors compared between the two stocks.

About BioNexus Gene Lab

BioNexus Gene Lab Corp., through its subsidiary, sells chemical raw material products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company offers chemical raw material products, which include Polyester Resin SHCP 268, a thixotropic, quick-curing unsaturated polyester resin suitable as a general-purpose resin; Polyester Resin 9509, a general-purpose material used in production of marine boats and water slides; and Polyester Resin 2802 used as a component in the pultrusion process by certain manufacturers. Its products are used to produce handrails, bench tops, automotive and aero parts, and paneling for hospital, laboratory, industrial clean rooms, and covers for various instruments used in manufacturing. The company also involves in developing and providing non-invasive liquid biopsy tests for the early detection of biomarkers to detect potential risk of diseases. It markets its products through its website, warehouse, marketing personnel, and suppliers. The company was incorporated in 2017 and is based in Kuala Lumpur, Malaysia.

About Selectis Health

Selectis Health owns and/or operates healthcare facilities in Arkansas, Georgia, Ohio, and Oklahoma, providing a wide array of living services, speech, occupational, physical therapies, social services, and other rehabilitation and healthcare services. Selectis focuses on building strategic relationships with local communities in which its partnership can improve the quality of care for facility residents. With its focused growth strategy, Selectis intends to deepen its American Southcentral and Southeastern market presence to better serve the aging population along a full continuum of care.